19 Biotechnology Stocks to Sell Now

19 Biotechnology Stocks to Sell Now

This week, the ratings of 19 Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Intercept Pharmaceuticals, Inc. (ICPT) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of ICPT stock.

Celgene Corporation (CELG) earns a D this week, moving down from last week’s grade of C. Celgene Corporation is a global integrated biopharmaceutical company engaged in the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. For more information, get Portfolio Grader’s complete analysis of CELG stock.

Alnylam Pharmaceuticals, Inc’s (ALNY) rating weakens this week, dropping to a F versus last week’s D. Alnylam Pharmaceuticals, Inc engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALNY stock.

This week, ACADIA Pharmaceuticals Inc. (ACAD) drops from a C to a D rating. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of ACAD stock.

Enanta Pharmaceuticals, Inc. (ENTA) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ENTA stock.

This week, Acorda Therapeutics, Inc.’s (ACOR) rating worsens to a F from the company’s D rating a week ago. Acorda Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The company also gets F’s in operating margin growth, earnings growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

OncoMed Pharmaceuticals, Inc. (OMED) declines this week from a C to a D. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of OMED stock.

Merrimack Pharmaceuticals, Inc. (MACK) gets weaker ratings this week as last week’s D drops to a F. Merrimack Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. The company also gets F’s in earnings revisions and free cash flow. For more information, get Portfolio Grader’s complete analysis of MACK stock.

This is a rough week for Kura Oncology, Inc. (KURA). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of KURA stock.

Synergy Pharmaceuticals, Inc. (SGYP) slips from a C to a D this week. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

Slipping from a C to a D rating, VistaGen Therapeutics, Inc. (VTGN) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VTGN stock.

This is a rough week for Prana Biotechnology Ltd Sponsored ADR (PRAN). The company’s rating falls to D from the previous week’s C. Prana Biotechnology Ltd Sponsored ADR is an Australian biotechnology company which researches and develops therapeutic drugs used for treatment of Alzheimer’s Disease and other age-related degenerative disorders such as Parkinson’s Disease and cataracts. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRAN stock.

This week, Capricor Therapeutics, Inc.’s (CAPR) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of CAPR stock.

Anavex Life Sciences Corp. (AVXL) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of AVXL stock.

Slipping from a D to a F rating, Tenax Therapeutics, Inc. (TENX) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TENX stock.

Aviragen Therapeutics Inc (AVIR) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AVIR stock.

RXi Pharmaceuticals Corporation (RXII) slips from a D to a F this week. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RXII stock.

AmpliPhi BioSciences Corporation (APHB) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in operating margin growth, earnings growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of APHB stock.

This week, Hemispherx Biopharma, Inc. (HEB) drops from a C to a D rating. Hemispherx Biopharma, Inc. engages in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of HEB stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/10/19-biotechnology-stocks-to-sell-now-3/.

©2019 InvestorPlace Media, LLC